greeksoup/ stock research

Veeva Systems (VEEV) FY2026 results: revenue $3.2 billion, up 16.3% on the year

Veeva Systems Inc. (VEEV) reported revenue of $3.2 billion for fiscal 2026, the year ended 31 January 2026, up 16.3% on the year before. Net income was $909 million, up 27.3%, and diluted earnings per share $5.44. The figures are the company's own, from the 10-K it filed with the SEC on 20 March 2026.

Revenue
$3.2 billion
+16.3% on the year
FY2019FY2026
Operating margin
28.7%
25.2% a year earlier
FY2019FY2026
Net income
$909 million
+27.3% on the year
FY2019FY2026
Diluted EPS
$5.44
+25.9% on the year
FY2019FY2026

this yearthe year beforeHover a bar for its figure.

The year in brief

What management said about the year

Guidance figures: 3 new.

  • Fourth quarter revenue up 16%: Q4 total revenues were $836.0 million, up 16%, against the $807 to $810 million range given in the November release. Subscription revenues were $707.7 million.
  • Fiscal 2026 revenue reached $3.2 billion: Fiscal 2026 total revenues were $3,195.3 million, up 16%. Subscription revenues were $2,684.2 million, up 17%, and professional services and other revenues were $511.1 million.
  • First quarter guidance issued: For the quarter ending April 30, 2026, total revenues are guided between $855 and $858 million, non-GAAP operating income between $378 and $381 million, and non-GAAP diluted EPS between $2.13 and $2.14.
  • Fiscal 2027 revenue guided: For the fiscal year ending January 31, 2027, total revenues are guided between $3,585 and $3,600 million. The earlier figures are not in these documents.
  • Vault CRM live customers above 125: More than 125 customers are live on Vault CRM, up from 115 at the November release, including two top 20 biopharmas in major markets.
Read the Q4 FY2026 earnings call summary

From this 10-K

Veeva sells industry cloud software, data and business consulting to the life sciences industry, covering research and development through to commercialisation. It served 1,552 customers as of 31 January 2026, across pharmaceutical, biotechnology and medical device companies, contract sales organisations and contract research organisations. The products sit in four categories, Veeva Development Cloud, Veeva Quality Cloud, Veeva Commercial Cloud and Veeva Data Cloud, reported as Commercial Solutions, covering Commercial Cloud and Data Cloud, and R&D and Quality Solutions, covering Development Cloud and Quality Cloud. Veeva AI adds agentic artificial intelligence to the Veeva Vault platform along with industry-specific agents that work inside the applications with direct access to data, documents and workflows.

Veeva Systems Inc., the 10-K for 2026

Veeva sells industry cloud software, data and business consulting to the life sciences industry, covering research and development through to commercialisation. It served 1,552 customers as of 31 January 2026, across pharmaceutical, biotechnology and medical device companies, contract sales organisations and contract research organisations. The products sit in four categories, Veeva Development Cloud, Veeva Quality Cloud, Veeva Commercial Cloud and Veeva Data Cloud, reported as Commercial Solutions, covering Commercial Cloud and Data Cloud, and R&D and Quality Solutions, covering Development Cloud and Quality Cloud. Veeva AI adds agentic artificial intelligence to the Veeva Vault platform along with industry-specific agents that work inside the applications with direct access to data, documents and workflows.

Veeva is a Delaware public benefit corporation, so its directors have a fiduciary duty to balance the financial interests of stockholders with the interests of other stakeholders and with the pursuit of its stated public benefit purpose, which its certificate of incorporation gives as helping make the industries it serves more productive and creating high-quality employment in the communities where it operates.

Development Cloud

Built on the Veeva Vault platform, this covers the clinical, regulatory and safety functions. The Veeva Clinical Platform connects the parties in a trial, being patients, research sites, contract research organisations and trial sponsors, with applications letting sites manage study documents electronically and exchange information securely. Veeva Clinical Data Management holds Veeva EDC for electronic data capture, Veeva CDB for aggregating, cleaning and transforming clinical data, and tools for electronic consents and participant assessments. The Veeva Clinical Operations Suite holds Veeva eTMF as the electronic trial master file, Veeva CTMS for trial management, and randomisation and trial supply management.

Veeva Safety manages drug safety content, reporting and analytics, the detection of safety signals, and the intake, processing and submission of adverse event data. Veeva RIM handles regulatory information management, letting a company manage, track and report product and registration information and plan, author, publish and archive submissions to healthcare authorities.

Quality Cloud

This unifies quality applications and processes across content management, training, quality assurance and quality control lab work on the Vault platform, for customers in life sciences and consumer products. It holds Veeva QMS for integrated quality processes, Veeva Quality Docs for regulated quality content, lab solutions covering batch release testing, stability study management and environmental monitoring, and training solutions.

Commercial Cloud

The Veeva Vault CRM Suite brings sales, marketing, medical and service teams at pharmaceutical and biotechnology companies into a single Vault database with shared data and content, to manage and track engagement with healthcare professionals. It carries the full functionality of the legacy Veeva CRM plus Campaign Manager for coordinating engagement channels, Patient CRM for patient services, and AI agents that give pre-call insights, allow voice-activated data entry and flag potential issues in call notes. Veeva CRM and some related applications are built on a platform provided by Salesforce, and the filing states they will be supported until 31 December 2029.

Veeva Medical gives medical affairs teams a single validated source of medical content. Veeva PromoMats is the content and digital asset management product for collaborating on, reviewing, distributing and updating commercial content, with AI agents assisting document review. Veeva Crossix provides marketing analytics and audience targeting for biopharmaceutical brands.

Data Cloud

Veeva OpenData is customer reference data, covering demographic, license and specialty information, affiliations and other data about healthcare professionals and organisations. Veeva Link combines software automation with human curation to provide deep data on key people, key accounts, publications, conferences, medical insights and digital engagement. Veeva Compass is described as de-identified U.S. longitudinal patient, projected prescriber and national data, used for business planning, patient finding, segmentation and targeting, forecasting and incentive compensation. Veeva HCP Access is a data subscription giving access and multichannel engagement metrics about healthcare professionals.

The services

Professional services cover implementation and deployment planning and project management, requirements analysis, solution design and configuration, managed services such as outsourced systems administration, technical consulting on data migration and systems integration, and training. Those teams work alongside systems integrator partners, and Veeva Services Partners add program management, support, training, customisation and integration.

Veeva Business Consulting sits separately from professional services. Commercial Business Consulting works on a specific customer initiative, commercial strategy or process change such as digital engagement, commercial content management, field optimisation, or commercial insights and analytics. R&D Business Consulting works across the drug development value chain on process efficiency, time to market and operating model and governance.

From Veeva Systems' annual report on Form 10-K for the year ended 31 January 2026. The filing

Written from the 10-K filed 20 March 2026: read the full 10-K.

The four quarters: Q1 FY2026 · Q2 FY2026 · Q3 FY2026 · Q4 FY2026

Income statement (profit and loss)

$ millionFY2026FY2025FY2024On the yearLast 8 years
Revenue3,1952,7472,364+16.3%
Cost of revenue782700677+11.8%
Gross profit2,4132,0471,686+17.9%
Gross margin75.5%74.5%71.3%
Research and development767693629+10.7%
Operating income916691429+32.5%
Operating margin28.7%25.2%18.2%
Pre-tax income1,195919588+29.9%
Income tax28620562.3+39.2%
Effective tax rate23.9%22.3%10.6%
Net income909714526+27.3%
Net margin28.4%26.0%22.2%
Diluted EPS$5.44$4.32$3.22+25.9%
$ million except per share.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow

$ millionFY2026FY2025FY2024On the yearLast 8 years
Operating cash flow1,4151,090911+29.8%
Cash from investing-1,104-700-1,076
Cash from financing-9.326.1-16.2
Depreciation and amortisationn/an/a25.0
Share-based compensation473437394+8.1%
Buybacks1700.00.0
Diluted shares, weighted167m165m163m+1.1%
Shares outstanding at period end164m163m161m+0.7%

Balance sheet

$ millionFY2026FY2025FY2024On the yearLast 8 years
Shareholders' equity7,2155,8324,645+23.7%
Debt0.00.00.0
Operating lease liabilities83.765.846.4+27.2%
Other liabilities1,6811,4421,220+16.6%
Total liabilities and equity8,9797,3405,911+22.3%
Fixed assets70.355.958.5+25.7%
Goodwill4404404400.0%
Intangible assets30.344.563.0-31.8%
Investments5,1404,0313,324+27.5%
Cash and equivalents1,4211,119703+27.0%
Receivables1,2601,016852+23.9%
Other assets618633470-2.3%
Total assets8,9797,3405,911+22.3%

10-K for the year ended 31 January 2026, filed 20 March 2026: the filing.